Skip to main content

Advertisement

SpringerLink
Log in

Predictive factors of response to vismodegib: a French study of 61 patients with multiple or locally advanced basal cell carcinoma

  • Therapy
  • Published:
European Journal of Dermatology

Abstract

Background

Vismodegib is indicated for the treatment of advanced or metastatic basal cell carcinoma (BCC). The predictive factors of response to vismodegib have so far been poorly described.

Objectives

The primary objective was to determine the profile of patients responding to vismodegib and the duration of response. Secondary objectives were to assess whether there is a correlation between the duration of treatment and the risk of relapse, and to define factors associated with relapse.

Materials & Methods

We included 61 patients with locally advanced BCC (laBCC) or multiple BCC, treated with vismodegib (150 mg per day), from July 2011 to November 2015, in the Oncodermatology Department of Nantes University Hospital in France. Tumour response was assessed using Response Evaluation Criteria in Solid Tumours version 1.1.

Results

Thirty-nine patients had advanced BCC (64%) and 22 patients multiple BCC (36%), including 10 patients with Gorlin syndrome. No factor predicted response to vismodegib. The median progression-free survival (PFS) was 69.5 months for the total population. In multivariate analysis, multiple BCC was the only factor associated with an increased risk of relapse (HR: 13.80 [CI95%, 1.93–98.64, p < 0.01]). Treatment duration decreased the risk of relapse (HR 0.95 [CI95%, 0.90–0.99, p = 0.0467]). Among the 20 patients who experienced relapse during follow-up, 15 (75%) were re-treated with vismodegib, with a response rate of 66%.

Conclusion

Although we were unable to establish predictive factors for the response to vismodegib, we demonstrate for the first time that increased treatment duration correlates with a decreased risk of relapse.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Cameron MC, Lee E, Hibler BP, et al. Basal cell carcinoma. J Am Acad Dermatol 2019; 80: 321–39.

    Article  PubMed  Google Scholar 

  2. Marzuka AG, Book SE. Basal cell carcinoma: pathogenesis, epidemiology, clinical features, diagnosis, histopathology and management. YaleJBiol Med 2015; 88: 167–79.

    Google Scholar 

  3. Rubin AI, Chen EH, Ratner D. Basal-cell carcinoma. N Engl J Med 2005; 353: 2262–9.

    Article  CAS  PubMed  Google Scholar 

  4. Amici JM, Battistella M, Beylot-Barry M, et al. Defining and recognising locally advanced basal cell carcinoma. Eur J Dermatol 2015; 25: 586–94.

    Article  PubMed  Google Scholar 

  5. Goldenberg G, Karagiannis T, Palmer JB, et al. Incidence and prevalence of basal cell carcinoma (BCC) and locally advanced BCC (LABCC) in a large commercially insured population in the United States: a retrospective cohort study. J Am Acad Dermatol 2016; 75: 957–66.

    Article  PubMed  Google Scholar 

  6. Lacouture ME, Dréno B, Ascierto PA, et al. Characterization and management of hedgehog pathway inhibitor-related adverse events in patients with advanced basal cell carcinoma. Oncologist 2016; 21: 1218–29.

    Article  PubMed  PubMed Central  Google Scholar 

  7. Lorusso PM, Jimeno A, Dy G, et al. Pharmacokinetic dosescheduling study of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with locally advanced or metastatic solid tumors. Clin Cancer Res 2011; 17: 5774–82.

    Article  CAS  PubMed  Google Scholar 

  8. Tang JY, Mackay-Wiggan JM, Aszterbaum M, et al. Inhibiting the hedgehog pathway in patients with the basal-cell nevus syndrome. N Engl J Med 2012; 366: 2180–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Sekulic A, Migden MR, Oro AE, et al. Efficacy and safety of vismodegib in advanced basal-cell carcinoma. N Engl J Med 2012; 366: 2171–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Basset-Séguin N, Hauschild A, Kunstfeld R, et al. Vismodegib in patients with advanced basal cell carcinoma: Primary analysis of STE-VIE, an international, open-label trial. Eur J Cancer 2017; 86: 334–48.

    Article  PubMed  Google Scholar 

  11. Dréno B, Kunstfeld R, Hauschild A, et al. Two intermittent vismodegib dosing regimens in patients with multiple basal-cell carcinomas (MIKIE): a randomised, regimen-controlled, double-blind, phase 2 trial. Lancet Oncol 2017; 18: 404–12.

    Article  PubMed  Google Scholar 

  12. Chang ALS, Solomon JA, Hainsworth JD, et al. Expanded access study of patients with advanced basal cell carcinoma treated with the Hedgehog pathway inhibitor, vismodegib. J Am Acad Dermatol 2014; 70: 60–9.

    Article  CAS  PubMed  Google Scholar 

  13. Castillo J-M, Knol A-C, Nguyen J-M, Khammari A, Saint-Jean M, Dreno B. Immunohistochemical markers of advanced basal cell carcinoma: CD56 is associated with a lack of response to vismodegib. Eur J Dermatol 2016; 26: 452–9.

    Article  CAS  PubMed  Google Scholar 

  14. Herms F, Lambert J, Grob J-J, et al. Follow-up of patients with complete remission of locally advanced basal cell carcinoma after vismodegib discontinuation: a multicenter French study of 116 patients. J Clin Oncol 2019; 37: 3275–82.

    Article  CAS  PubMed  Google Scholar 

  15. Apalla Z, Spyridis I, Kyrgidis A, et al. Vismodegib in real-life clinical settings: a multicenter, longitudinal cohort providing long-term data on efficacy and safety. J Am Acad Dermatol 2021; 85: 1589–92.

    Article  CAS  PubMed  Google Scholar 

  16. Verkouteren BJA, Wakkee M, Reyners AKL, et al. Eight years of experience with vismodegib for advanced and multiple basal cell carcinoma patients in the Netherlands: a retrospective cohort study. Br J Cancer 2021; 124: 1199–206.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECISTguideline (version 1.1). Eur J Cancer 2009; 45: 22847.

    Article  Google Scholar 

  18. Chebassier N, El Houssein O, Viegas I, Dréno B. In vitro induction of matrix metalloproteinase-2 and matrix metalloproteinase-9 expression in keratinocytes by boron and manganese. Exp Dermatol 2004; 13: 484–90.

    Article  CAS  PubMed  Google Scholar 

  19. Saintes C, Saint-Jean M, Brocard A, et al. Development of squamous cell carcinoma into basal cell carcinoma under treatment with Vismodegib. J Eur Acad Dermatol Venereol 2015; 29: 1006–9.

    Article  CAS  PubMed  Google Scholar 

  20. Sekulic A, Migden MR, Basset-Seguin N, et al. Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC study. BMC Cancer 2017; 17: 332.

    Article  PubMed  PubMed Central  Google Scholar 

  21. Xie P, Lefrancois P. Efficacy, safety, and comparison of sonic hedgehog inhibitors in basal cell carcinomas: a systematic review and meta-analysis. J Am Acad Dermatol 2018; 79: 1089–100.

    Article  CAS  PubMed  Google Scholar 

  22. Flohil SC, van der Leest RJT, Arends LR, de Vries E, Nijsten T. Risk of subsequent cutaneous malignancy in patients with prior keratinocyte carcinoma: a systematic review and meta-analysis. Eur J Cancer 2013; 49: 2365–75.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Dermatology, Nantes University Hospital, 1 place Alexis Ricordeau, 44093, Nantes Cedex 1, France

    Cécile Juzot, Anne Isvy-Joubert, Amir Khammari & Brigitte Dreno

  2. CRCNA, INSERM U892, CNRS 6299, 9 Quai Moncousu, 44093, Nantes, France

    Amir Khammari, Anne-Chantal Knol & Jean-Michel Nguyen

  3. Epidemiology and Biostatistics Department, CRCINA, INSERM1232, Nantes University Hospital, 85 Rue Saint-Jacques, 44093, Nantes, France

    Jean-Michel Nguyen

  4. Department of Dermatology, CIC 1413, CRCINA, Nantes University Hospital, 1 place Alexis Ricordeau, 44093, Nantes Cedex 1, France

    Brigitte Dreno

Authors
  1. Cécile Juzot
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Anne Isvy-Joubert
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Amir Khammari
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Anne-Chantal Knol
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Jean-Michel Nguyen
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Brigitte Dreno
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Brigitte Dreno.

Additional information

Funding sources

none

Conflicts of interest

none

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Juzot, C., Isvy-Joubert, A., Khammari, A. et al. Predictive factors of response to vismodegib: a French study of 61 patients with multiple or locally advanced basal cell carcinoma. Eur J Dermatol 32, 401–407 (2022). https://doi.org/10.1684/ejd.2022.4264

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1684/ejd.2022.4264

Key words

Search

Navigation